190 related articles for article (PubMed ID: 21304219)
1. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid.
Schipke CG; Prokop S; Heppner FL; Heuser I; Peters O
Dement Geriatr Cogn Disord; 2011; 31(2):139-45. PubMed ID: 21304219
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
Paternicò D; Galluzzi S; Drago V; Bocchio-Chiavetto L; Zanardini R; Pedrini L; Baronio M; Amicucci G; Frisoni GB
Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
[TBL] [Abstract][Full Text] [Related]
4. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1-40, (Abeta40), beta-amyloid 1-42 (Abeta42) and total Tau.
Stuerenburg HJ; Ganzer S; Müller-Thomsen T
Neuro Endocrinol Lett; 2005 Dec; 26(6):696-8. PubMed ID: 16380679
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
Zetterberg H; Blennow K
J Alzheimers Dis; 2013; 33 Suppl 1():S361-9. PubMed ID: 22710917
[TBL] [Abstract][Full Text] [Related]
6. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.
Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Touchon J; Perret-Liaudet A; Lehmann S
Brain Res; 2010 Oct; 1357():175-83. PubMed ID: 20713025
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
9. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
10. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration.
Petzold A; Verwey NA; van Uffelen K; Blankenstein MA; Teunissen C
J Neurosci Methods; 2010 Nov; 193(2):296-9. PubMed ID: 20832428
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
12. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?
Koric L; Felician O; Guedj E; Hubert AM; Mancini J; Boucraut J; Ceccaldi M
Alzheimer Dis Assoc Disord; 2010; 24(3):278-83. PubMed ID: 20473135
[TBL] [Abstract][Full Text] [Related]
13. [Biomarkers in spinal fluid of patients with dementia].
Skogseth RE; Fladby T; Mulugeta E; Aarsland D
Tidsskr Nor Laegeforen; 2011 Nov; 131(22):2235-8. PubMed ID: 22085948
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
15. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
Vanderstichele H; Bibl M; Engelborghs S; Le Bastard N; Lewczuk P; Molinuevo JL; Parnetti L; Perret-Liaudet A; Shaw LM; Teunissen C; Wouters D; Blennow K
Alzheimers Dement; 2012 Jan; 8(1):65-73. PubMed ID: 22047631
[TBL] [Abstract][Full Text] [Related]
16. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
[TBL] [Abstract][Full Text] [Related]
17. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid.
Schipke CG; Jessen F; Teipel S; Luckhaus C; Wiltfang J; Esselmann H; Frölich L; Maier W; Rüther E; Heppner FL; Prokop S; Heuser I; Peters O
J Alzheimers Dis; 2011; 26(2):255-62. PubMed ID: 21606567
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
19. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
[TBL] [Abstract][Full Text] [Related]
20. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
